Anthracyclines cause cumulative dose-dependent cardiotoxicity leading to heart failure, requiring specific methods for detection, prevention, and treatment.
Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition.
Волкова et al. (Tue,) studied this question.